# Antonello Mai

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 333 papers | 12,479 citations | 59 h-index | 92 g-index |
| 375 ext. papers | 14,373 ext. citations | 6.3 avg, IF | 6.16 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 333 | A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression.. *International Journal of Antimicrobial Agents*, **2022**, 106526 | 14.3 | 1 |
| 332 | Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription.. *Nucleic Acids Research*, **2022**, | 20.1 | 2 |
| 331 | Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules.. *Theranostics*, **2022**, 12, 2427-2444 | 12.1 | 0 |
| 330 | Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.. *Journal of Cachexia, Sarcopenia and Muscle*, **2022**, | 10.3 | 3 |
| 329 | Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2022**, 37, 973-985 | 5.6 | 0 |
| 328 | Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors.. *EMBO Reports*, **2022**, e54721 | 6.5 | 1 |
| 327 | Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.. *European Journal of Medicinal Chemistry*, **2022**, 237, 114410 | 6.8 | 0 |
| 326 | First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. *Journal of Medicinal Chemistry*, **2021**, 64, 17031-17050 | 8.3 | 0 |
| 325 | Sirtuins **2021**, 1422-1435 | | |
| 324 | The Two-Faced Role of SIRT6 in Cancer. *Cancers*, **2021**, 13, | 6.6 | 8 |
| 323 | Emerging Therapeutic Potential of SIRT6 Modulators. *Journal of Medicinal Chemistry*, **2021**, 64, 9732-9758 | 8.3 | 7 |
| 322 | Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. *Gastroenterology*, **2021**, 161, 1584-1600 | 13.3 | 8 |
| 321 | Downregulation of miR-326 and its host gene β-arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth. *Molecular Oncology*, **2021**, 15, 523-542 | 7.9 | 5 |
| 320 | Novel Pyridine-Based Hydroxamates and 2-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. *ChemMedChem*, **2021**, 16, 989-999 | 3.7 | 2 |
| 319 | Amphetamine Modulation of Long-Term Object Recognition Memory in Rats: Influence of Stress. *Frontiers in Pharmacology*, **2021**, 12, 644521 | 5.6 | 0 |
| 318 | Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer. *Cancers*, **2021**, 13, | 6.6 | 5 |
| 317 | Histone-deacetylase 8 drives the immune response and the growth of glioma. *Glia*, **2021**, 69, 2682-2698 | 9 | 3 |

| | | | |
|---|---|---|---|
| 316 | Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders. *Journal of Medicinal Chemistry*, **2021**, 64, 11774-11797 | 8.3 | 7 |
| 315 | Anti-influenza A virus activity and structure-activity relationship of a series of nitrobenzoxadiazole derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2021**, 36, 2128-2138 | 5.6 | 0 |
| 314 | Mass spectrometry enables the discovery of inhibitors of an LPS transport assembly disruption of protein-protein interactions. *Chemical Communications*, **2021**, 57, 10747-10750 | 5.8 | 1 |
| 313 | Diphenylene Iodonium Is a Noncovalent MAO Inhibitor: A Biochemical and Structural Analysis. *ChemMedChem*, **2020**, 15, 1394-1397 | 3.7 | 1 |
| 312 | Detrimental effects of the bath salt methylenedioxypyrovalerone on social play behavior in male rats. *Neuropsychopharmacology*, **2020**, 45, 2012-2019 | 8.7 | 4 |
| 311 | Identification of Inhibitors to Sirtuins Based on Compounds Developed to Human Enzymes. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 7 |
| 310 | The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. *Frontiers in Oncology*, **2020**, 10, 820 | 5.3 | 4 |
| 309 | Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. *ACS Medicinal Chemistry Letters*, **2020**, 11, 977-983 | 4.3 | 23 |
| 308 | Sirtuin modulators: where are we now? A review of patents from 2015 to 2019. *Expert Opinion on Therapeutic Patents*, **2020**, 30, 389-407 | 6.8 | 18 |
| 307 | The Innovative Potential of Statins in Cancer: New Targets for New Therapies. *Frontiers in Chemistry* , **2020**, 8, 516 | 5 | 34 |
| 306 | Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008332 | 4.8 | 5 |
| 305 | Targeting histone acetylation/deacetylation in parasites: an update (2017-2020). *Current Opinion in Chemical Biology*, **2020**, 57, 65-74 | 9.7 | 16 |
| 304 | Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. *Cancers*, **2020**, 12, | 6.6 | 3 |
| 303 | A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. *Redox Biology*, **2020**, 32, 101466 | 11.3 | 28 |
| 302 | Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. *ChemMedChem*, **2020**, 15, 643-658 | 3.7 | 9 |
| 301 | Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene. *Human Genetics*, **2020**, 139, 227-245 | 6.3 | 11 |
| 300 | Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer. *Frontiers in Oncology*, **2020**, 10, 474 | 5.3 | 15 |
| 299 | Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation. *Science Advances*, **2020**, 6, eaax2746 | 14.3 | 23 |

| | | | |
|---|---|---|---|
| 298 | Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. *EMBO Reports*, **2020**, 21, e51028 | 6.5 | 0 |
| 297 | HAT inhibitors in cancer therapy **2020**, 51-80 | | 1 |
| 296 | Inhibition of class I HDACs imprints adipogenesis toward oxidative and brown-like phenotype. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158594 | 5 | 7 |
| 295 | Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). *European Journal of Medicinal Chemistry*, **2020**, 207, 112750 | 6.8 | 5 |
| 294 | From PARP1 to TNKS2 Inhibition: A Structure-Based Approach. *ACS Medicinal Chemistry Letters*, **2020**, 11, 862-868 | 4.3 | 3 |
| 293 | Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. *Molecules*, **2020**, 25, | 4.8 | 3 |
| 292 | Lysine Acetyltransferase Inhibitors From Natural Sources. *Frontiers in Pharmacology*, **2020**, 11, 1243 | 5.6 | 6 |
| 291 | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. *Frontiers in Pharmacology*, **2020**, 11, 1230 | 5.6 | 9 |
| 290 | Epigenetic polypharmacology: A new frontier for epi-drug discovery. *Medicinal Research Reviews*, **2020**, 40, 190-244 | 14.4 | 49 |
| 289 | Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization. *ACS Chemical Biology*, **2020**, 15, 1349-1357 | 4.9 | 2 |
| 288 | Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni **2020**, 14, e0008332 | | |
| 287 | Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni **2020**, 14, e0008332 | | |
| 286 | Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni **2020**, 14, e0008332 | | |
| 285 | Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni **2020**, 14, e0008332 | | |
| 284 | Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from (Sirt2). *Journal of Medicinal Chemistry*, **2019**, 62, 8733-8759 | 8.3 | 12 |
| 283 | Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. *Clinical Epigenetics*, **2019**, 11, 11 | 7.7 | 35 |
| 282 | Epigenetic Pharmacology in Regenerative Medicine (Epi-Drugs) **2019**, 405-444 | | |
| 281 | Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. *Molecular Neurobiology*, **2019**, 56, 8018-8034 | 6.2 | 9 |

| | | | |
|---|---|---|---|
| 280 | Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. *Clinical Epigenetics*, **2019**, 11, 68 | 7.7 | 18 |
| 279 | Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. *Current Opinion in Chemical Biology*, **2019**, 50, 89-100 | 9.7 | 18 |
| 278 | Comparison of the effects of synthetic and plant-derived mTOR regulators on healthy human ovarian cells. *European Journal of Pharmacology*, **2019**, 854, 70-78 | 5.3 | 3 |
| 277 | Statins and Histone Deacetylase Inhibitors Affect Lamin A/C - Histone Deacetylase 2 Interaction in Human Cells. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 6 | 5.7 | 14 |
| 276 | Sirtuins as Drug Targets. *Methods and Principles in Medicinal Chemistry*, **2019**, 185-200 | 0.4 | 1 |
| 275 | H19-Dependent Transcriptional Regulation of 3 and 4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 13 |
| 274 | The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells. *Scientific Reports*, **2019**, 9, 15925 | 4.9 | 20 |
| 273 | Epigenetic Metalloenzymes. *Current Medicinal Chemistry*, **2019**, 26, 2748-2785 | 4.3 | 7 |
| 272 | DNA Methylation: Biological Implications and Modulation of Its Aberrant Dysregulation. *RNA Technologies*, **2019**, 295-331 | 0.2 | |
| 271 | The emerging role of epigenetics in human autoimmune disorders. *Clinical Epigenetics*, **2019**, 11, 34 | 7.7 | 97 |
| 270 | Diketocarboxylic Acids and Their Esters Act as Carbonic Anhydrase IX and XII Selective Inhibitors. *ACS Medicinal Chemistry Letters*, **2019**, 10, 661-665 | 4.3 | 12 |
| 269 | Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 8 |
| 268 | Inhibition of Histone Demethylases LSD1 and UTX Regulates ER Signaling in Breast Cancer. *Cancers*, **2019**, 11, | 6.6 | 19 |
| 267 | Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype. *Clinical Epigenetics*, **2019**, 11, 173 | 7.7 | 27 |
| 266 | Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone (MDPV) Induce Generalization of Fear Memory in Rats. *Frontiers in Molecular Neuroscience*, **2019**, 12, 292 | 6.1 | 6 |
| 265 | Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells. *European Journal of Medicinal Chemistry*, **2019**, 163, 722-735 | 6.8 | 7 |
| 264 | Intergenerational inheritance of high fat diet-induced cardiac lipotoxicity in Drosophila. *Nature Communications*, **2019**, 10, 193 | 17.4 | 20 |
| 263 | Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. *Journal of Psychopharmacology*, **2019**, 33, 392-405 | 4.6 | 13 |

| | | | |
|---|---|---|---|
| 262 | Identification of novel quinazoline derivatives as potent antiplasmodial agents. *European Journal of Medicinal Chemistry*, **2019**, 161, 277-291 | 6.8 | 25 |
| 261 | Effect of Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones. *Journal of Medicinal Chemistry*, **2019**, 62, 604-621 | 8.3 | 10 |
| 260 | Lysine acetyltransferase inhibitors: structure-activity relationships and potential therapeutic implications. *Future Medicinal Chemistry*, **2018**, 10, 1067-1091 | 4.1 | 17 |
| 259 | Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2018**, 373, | 5.8 | 11 |
| 258 | Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches. *Journal of Computer-Aided Molecular Design*, **2018**, 32, 435-458 | 4.2 | 11 |
| 257 | Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. *Nature Communications*, **2018**, 9, 53 | 17.4 | 116 |
| 256 | KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2. *Clinical Epigenetics*, **2018**, 10, 44 | 7.7 | 6 |
| 255 | RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. *Clinical Cancer Research*, **2018**, 24, 2886-2900 | 12.9 | 24 |
| 254 | Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice. *Neuroscience*, **2018**, 379, 228-238 | 3.9 | 16 |
| 253 | Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS. *Aging Cell*, **2018**, 17, e12824 | 9.9 | 21 |
| 252 | Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers. *Psychopharmacology*, **2018**, 235, 2831-2846 | 4.7 | 6 |
| 251 | Combined HAT/EZH2 modulation leads to cancer-selective cell death. *Oncotarget*, **2018**, 9, 25630-25646 | 3.3 | 5 |
| 250 | Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. *Oncotarget*, **2018**, 9, 25647-25660 | 3.3 | 11 |
| 249 | EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers. *Frontiers in Pediatrics*, **2018**, 6, 328 | 3.4 | 10 |
| 248 | Application of Small Epigenetic Modulators in Pediatric Medulloblastoma. *Frontiers in Pediatrics*, **2018**, 6, 370 | 3.4 | 8 |
| 247 | Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. *Cell Death and Disease*, **2018**, 9, 996 | 9.8 | 49 |
| 246 | Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds. *Chemical Record*, **2018**, 18, 1818-1832 | 6.6 | 50 |
| 245 | HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal. *Scientific Reports*, **2018**, 8, 8492 | 4.9 | 10 |

| | | | |
|---|---|---|---|
| 244 | A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. *Molecular Cancer Therapeutics*, **2018**, 17, 1881-1892 | 6.1 | 22 |
| 243 | A new nitrobenzoxadiazole-based GSTP1-1 inhibitor with a previously unheard of mechanism of action and high stability. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 240-247 | 5.6 | 10 |
| 242 | Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. *Scientific Reports*, **2017**, 7, 44079 | 4.9 | 43 |
| 241 | Metabolite profiling of ascidian Styela plicata using LC-MS with multivariate statistical analysis and their antitumor activity. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 614-623 | 5.6 | 15 |
| 240 | Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. *Journal of Medicinal Chemistry*, **2017**, 60, 4780-4804 | 8.3 | 53 |
| 239 | Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 2344-2360 | 8.3 | 61 |
| 238 | Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. *European Journal of Medicinal Chemistry*, **2017**, 134, 316-333 | 6.8 | 13 |
| 237 | EZH2 inhibitors: a patent review (2014-2016). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 797-813 | 6.8 | 32 |
| 236 | The relevance of K calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. *European Journal of Medicinal Chemistry*, **2017**, 136, 480-486 | 6.8 | 5 |
| 235 | Structure-Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. *ChemMedChem*, **2017**, 12, 1359-1368 | 3.7 | 9 |
| 234 | Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 847-856 | 3.4 | 9 |
| 233 | Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. *Angewandte Chemie - International Edition*, **2017**, 56, 1007-1011 | 16.4 | 80 |
| 232 | Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. *Angewandte Chemie*, **2017**, 129, 1027-1031 | 3.6 | 3 |
| 231 | Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice. *Neuroscience Letters*, **2017**, 656, 120-125 | 3.3 | 14 |
| 230 | Crystal structures of the mitochondrial deacylase Sirtuin 4 reveal isoform-specific acyl recognition and regulation features. *Nature Communications*, **2017**, 8, 1513 | 17.4 | 52 |
| 229 | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. *Clinical Epigenetics*, **2017**, 9, 59 | 7.7 | 93 |
| 228 | Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases. *International Journal of Obesity*, **2017**, 41, 289-298 | 5.5 | 32 |
| 227 | Essential Oil Extraction, Chemical Analysis and Anti-Candida Activity of Calamintha nepeta (L.) Savi subsp. glandulosa (Req.) Ball-New Approaches. *Molecules*, **2017**, 22, | 4.8 | 22 |

| | | | |
|---|---|---|---|
| 226 | The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. *Oncotarget*, **2017**, 8, 68557-68570 | 3.3 | 27 |
| 225 | Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors. *ChemMedChem*, **2016**, 11, 1680-5 | 3.7 | 11 |
| 224 | MC1568 inhibits HDAC6/8 activity and influenza A virus replication in lung epithelial cells: role of Hsp90 acetylation. *Future Medicinal Chemistry*, **2016**, 8, 2017-2031 | 4.1 | 18 |
| 223 | The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. *Cell*, **2016**, 167, 1145-1149 | 56.2 | 232 |
| 222 | Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features. *Science Advances*, **2016**, 2, e1601017 | 14.3 | 39 |
| 221 | Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1 and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model. *Autoimmunity*, **2016**, 1-11 | 3 | 12 |
| 220 | The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. *Biochemical Pharmacology*, **2016**, 102, 130-140 | 6 | 37 |
| 219 | 1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. *Journal of Medicinal Chemistry*, **2016**, 59, 1471-91 | 8.3 | 37 |
| 218 | Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. *Journal of Medicinal Chemistry*, **2016**, 59, 1501-17 | 8.3 | 50 |
| 217 | Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. *American Journal of Cancer Research*, **2016**, 6, 859-75 | 4.4 | 17 |
| 216 | Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. *Oncotarget*, **2016**, 7, 11332-48 | 3.3 | 36 |
| 215 | DNA Methyltransferases Inhibitors from Natural Sources. *Current Topics in Medicinal Chemistry*, **2016**, 16, 680-96 | 3 | 43 |
| 214 | LSD1 inhibitors: a patent review (2010-2015). *Expert Opinion on Therapeutic Patents*, **2016**, 26, 565-80 | 6.8 | 36 |
| 213 | Sirtuin functions and modulation: from chemistry to the clinic. *Clinical Epigenetics*, **2016**, 8, 61 | 7.7 | 176 |
| 212 | Chemical epigenetics to assess the role of HDAC1 inhibition in macrophage pro-inflammatory gene expression. *MedChemComm*, **2016**, 7, 2184-2190 | 5 | 4 |
| 211 | The emerging role of lysine methyltransferase SETD8 in human diseases. *Clinical Epigenetics*, **2016**, 8, 102 | 7.7 | 58 |
| 210 | Interplay among nucleosomal DNA, histone tails, and corepressor CoREST underlies LSD1-mediated H3 demethylation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 2752-7 | 11.5 | 54 |
| 209 | SIRT5 regulation of ammonia-induced autophagy and mitophagy. *Autophagy*, **2015**, 11, 253-70 | 10.2 | 155 |

| | | | |
|---|---|---|---|
| 208 | New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. *Journal of Biological Chemistry*, **2015**, 290, 6293-302 | 5.4 | 41 |
| 207 | Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. *Journal of Medicinal Chemistry*, **2015**, 58, 4073-9 | 8.3 | 45 |
| 206 | Emerging approaches for histone deacetylase inhibitor drug discovery. *Expert Opinion on Drug Discovery*, **2015**, 10, 599-613 | 6.2 | 47 |
| 205 | A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. *Biochemical Pharmacology*, **2015**, 95, 16-27 | 6 | 24 |
| 204 | A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach. *Journal of Medicinal Chemistry*, **2015**, 58, 2779-98 | 8.3 | 37 |
| 203 | Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. *European Neuropsychopharmacology*, **2015**, 25, 2036-48 | 1.2 | 38 |
| 202 | Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents. *ACS Chemical Biology*, **2015**, 10, 2589-97 | 4.9 | 45 |
| 201 | Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases. *European Journal of Medicinal Chemistry*, **2015**, 89, 156-71 | 6.8 | 24 |
| 200 | Identification of structural features of 2-alkylidene-1,3-dicarbonyl derivatives that induce inhibition and/or activation of histone acetyltransferases KAT3B/p300 and KAT2B/PCAF. *ChemMedChem*, **2015**, 10, 144-57 | 3.7 | 20 |
| 199 | Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. *ACS Medicinal Chemistry Letters*, **2015**, 6, 173-7 | 4.3 | 16 |
| 198 | Targeting Lysine Deacetylases (KDACs) in Parasites. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0004026 | 4.8 | 36 |
| 197 | Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. *European Journal of Medicinal Chemistry*, **2015**, 94, 163-74 | 6.8 | 25 |
| 196 | Enzyme kinetics and inhibition of histone acetyltransferase KAT8. *European Journal of Medicinal Chemistry*, **2015**, 105, 289-96 | 6.8 | 26 |
| 195 | Sirtuin modulators: an updated patent review (2012 - 2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 5-15 | 6.8 | 39 |
| 194 | Sirtuin function in aging heart and vessels. *Journal of Molecular and Cellular Cardiology*, **2015**, 83, 55-61 | 5.8 | 67 |
| 193 | Pyrrole- and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells. *MedChemComm*, **2015**, 6, 665-670 | 5 | 21 |
| 192 | A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. *Oncotarget*, **2015**, 6, 4126-43 | 3.3 | 18 |
| 191 | Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). *Expert Opinion on Therapeutic Patents*, **2014**, 24, 401-15 | 6.8 | 31 |

| | | | |
|---|---|---|---|
| 190 | Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: enzyme and cellular studies. *European Journal of Medicinal Chemistry*, **2014**, 80, 569-78 | 6.8 | 43 |
| 189 | Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. *Biochemical Pharmacology*, **2014**, 91, 181-90 | 6 | 20 |
| 188 | Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells. *Journal of Medicinal Chemistry*, **2014**, 57, 701-13 | 8.3 | 84 |
| 187 | 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. *Journal of Medicinal Chemistry*, **2014**, 57, 6259-65 | 8.3 | 73 |
| 186 | Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. *Journal of Medicinal Chemistry*, **2014**, 57, 42-55 | 8.3 | 94 |
| 185 | Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. *BMC Cancer*, **2014**, 14, 139 | 4.8 | 48 |
| 184 | Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3797-801 | 2.9 | 31 |
| 183 | Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes. *Journal of Medicinal Chemistry*, **2014**, 57, 5212-25 | 8.3 | 15 |
| 182 | The histone acetylase activator pentadecylidenemalonate 1b rescues proliferation and differentiation in the human cardiac mesenchymal cells of type 2 diabetic patients. *Diabetes*, **2014**, 63, 2132-47 | 0.9 | 57 |
| 181 | Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity. *PLoS ONE*, **2014**, 9, e96941 | 3.7 | 29 |
| 180 | PRMT1 arginine methyltransferase accumulates in cytoplasmic bodies that respond to selective inhibition and DNA damage. *European Journal of Histochemistry*, **2014**, 58, 2389 | 2.1 | 9 |
| 179 | Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. *Journal of Molecular Cell Biology*, **2014**, 6, 116-27 | 6.3 | 26 |
| 178 | The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). *Oncogene*, **2014**, 33, 4173-84 | 9.2 | 49 |
| 177 | Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease. *Frontiers in Pharmacology*, **2014**, 5, 89 | 5.6 | 42 |
| 176 | Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. *European Journal of Medicinal Chemistry*, **2014**, 86, 352-63 | 6.8 | 41 |
| 175 | Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. *Cancer Research*, **2014**, 74, 2328-39 | 10.1 | 30 |
| 174 | Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells. *ChemMedChem*, **2014**, 9, 542-8 | 3.7 | 21 |
| 173 | Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. *International Journal of Biochemistry and Cell Biology*, **2014**, 50, 112-22 | 5.6 | 19 |

| | | | |
|---|---|---|---|
| 172 | IB kinase targets interferon regulatory factor 1 in activated T lymphocytes. *Molecular and Cellular Biology*, **2014**, 34, 1054-65 | 4.8 | 21 |
| 171 | Histone modifications, stem cells and prostate cancer. *Current Pharmaceutical Design*, **2014**, 20, 1687-97 | 3.3 | 9 |
| 170 | Screen of pseudopeptidic inhibitors of human sirtuins 1-3: two lead compounds with antiproliferative effects in cancer cells. *Journal of Medicinal Chemistry*, **2013**, 56, 6681-95 | 8.3 | 32 |
| 169 | Oxidative stress and epigenetic regulation in ageing and age-related diseases. *International Journal of Molecular Sciences*, **2013**, 14, 17643-63 | 6.3 | 162 |
| 168 | tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. *ChemMedChem*, **2013**, 8, 800-11 | 3.7 | 15 |
| 167 | Novel benzofuran-chromone and -coumarin derivatives: synthesis and biological activity in K562 human leukemia cells. *MedChemComm*, **2013**, 4, 1571 | 5 | 36 |
| 166 | Reactivity of 4-Vinyl-2H-1-benzopyran-2-ones in Diels-Alder Cycloaddition Reactions: Access to Coumarin-Based Polycycles with Cdc25 Phosphatase-Inhibiting Activity. *European Journal of Organic Chemistry*, **2013**, 2013, 2869-2877 | 3.2 | 9 |
| 165 | Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase. *ACS Chemical Biology*, **2013**, 8, 1677-82 | 4.9 | 50 |
| 164 | Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. *Diabetes*, **2013**, 62, 732-42 | 0.9 | 165 |
| 163 | Detrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemia. *Journal of Biological Chemistry*, **2013**, 288, 22915-29 | 5.4 | 26 |
| 162 | A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair. *Journal of Biological Chemistry*, **2013**, 288, 11004-12 | 5.4 | 58 |
| 161 | Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. *PLoS ONE*, **2013**, 8, e55786 | 3.7 | 50 |
| 160 | Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1. *Journal of Medicinal Chemistry*, **2012**, 55, 9875-90 | 8.3 | 18 |
| 159 | Screening assays for epigenetic targets using native histones as substrates. *Journal of Biomolecular Screening*, **2012**, 17, 18-26 | | 17 |
| 158 | Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead. *MedChemComm*, **2012**, 3, 298-304 | 5 | 6 |
| 157 | p300/CBP-associated factor selectively regulates the extinction of conditioned fear. *Journal of Neuroscience*, **2012**, 32, 11930-41 | 6.6 | 72 |
| 156 | Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction. *Journal of Chemical Information and Modeling*, **2012**, 52, 2215-35 | 6.1 | 22 |
| 155 | Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. *Journal of Medicinal Chemistry*, **2012**, 55, 8193-7 | 8.3 | 27 |

| | | | |
|---|---|---|---|
| 154 | An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. *Journal of Molecular Biology*, **2012**, 416, 319-27 | 6.5 | 49 |
| 153 | Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies. *ChemMedChem*, **2012**, 7, 1905-8 | 3.7 | 10 |
| 152 | The emerging role of histone lysine demethylases in prostate cancer. *Molecular Cancer*, **2012**, 11, 52 | 42.1 | 59 |
| 151 | Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. *Journal of Medicinal Chemistry*, **2012**, 55, 10937-47 | 8.3 | 70 |
| 150 | Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. *Biochimie*, **2012**, 94, 2308-13 | 4.6 | 24 |
| 149 | 6-(Arylmethyl)pyrimidin-4(3H)-ones: anthology and prospects of highly efficient anti-HIV agents. *Russian Chemical Bulletin*, **2012**, 61, 1399-1418 | 1.7 | 10 |
| 148 | 2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies. *Journal of Medicinal Chemistry*, **2012**, 55, 3558-62 | 8.3 | 26 |
| 147 | BLUEPRINT to decode the epigenetic signature written in blood. *Nature Biotechnology*, **2012**, 30, 224-6 | 44.5 | 261 |
| 146 | P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N(ε)-lysine acetylation of contractile proteins. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 2435-43 | 9.4 | 27 |
| 145 | Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E2284-93 | 11.5 | 32 |
| 144 | Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin. *Biochemical and Biophysical Research Communications*, **2011**, 408, 630-4 | 3.4 | 22 |
| 143 | Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. *Diabetes*, **2011**, 60, 2861-71 | 0.9 | 100 |
| 142 | Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones. *Journal of Medicinal Chemistry*, **2011**, 54, 8228-32 | 8.3 | 26 |
| 141 | Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. *Journal of Medicinal Chemistry*, **2011**, 54, 3051-64 | 8.3 | 42 |
| 140 | Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. *Aids*, **2011**, 25, 1347-56 | 3.5 | 65 |
| 139 | Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3RC-methyladenosine in leukaemia cells. *International Journal of Oncology*, **2011**, 38, 1427-36 | 4.4 | 4 |
| 138 | Application of 3 μm particle-based amylose-derived chiral stationary phases for the enantioseparation of potential histone deacetylase inhibitors. *Journal of Chromatography A*, **2011**, 1218, 8394-8 | 4.5 | 16 |
| 137 | Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity. *Journal of Medicinal Chemistry*, **2011**, 54, 4928-32 | 8.3 | 57 |

| | | | |
|---|---|---|---|
| 136 | Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. *Journal of Medicinal Chemistry*, **2011**, 54, 3091-6 | 8.3 | 44 |
| 135 | Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity. *ChemMedChem*, **2011**, 6, 698-712 | 3.7 | 13 |
| 134 | Biological effects of MC2050, a quinazoline-based PARP-1 inhibitor, in human neuroblastoma and EBV-positive Burkitt's lymphoma cells. *ChemMedChem*, **2011**, 6, 606-11 | 3.7 | 9 |
| 133 | Identification of small-molecule inhibitors of the XendoU endoribonucleases family. *ChemMedChem* , **2011**, 6, 1797-805 | 3.7 | 7 |
| 132 | A photoreactive small-molecule probe for 2-oxoglutarate oxygenases. *Chemistry and Biology*, **2011**, 18, 642-654 | | 44 |
| 131 | Photoactivable peptides for identifying enzyme-substrate and protein-protein interactions. *Chemical Communications*, **2011**, 47, 1488-90 | 5.8 | 5 |
| 130 | Epigenetic modulation of PGC-1α activity by GCN5 inhibitors: WO2010007085. *Expert Opinion on Therapeutic Patents*, **2011**, 21, 1651-6 | 6.8 | 7 |
| 129 | Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors. *Journal of Medicinal Chemistry*, **2011**, 54, 5927-36 | 8.3 | 11 |
| 128 | Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). *Bioorganic and Medicinal Chemistry*, **2011**, 19, 3690-701 | 3.4 | 27 |
| 127 | Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 3659-68 | 3.4 | 28 |
| 126 | HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. *Cancer Research* , **2011**, 71, 4412-22 | 10.1 | 132 |
| 125 | Histone deacetylase inhibitors (epigenetic alterations) **2011**, 62-72 | | |
| 124 | N-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 2795-800 | 11.5 | 82 |
| 123 | Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. *Genes and Cancer*, **2011**, 2, 663-79 | 2.9 | 156 |
| 122 | Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. *PLoS ONE*, **2011**, 6, e24307 | 3.7 | 49 |
| 121 | Identification of specific and semi-specific SIRT inhibitors through computer-aided studies. *Aging*, **2011**, 3, 819-20 | 5.6 | 1 |
| 120 | Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. *Oncogene*, **2010**, 29, 105-16 | 9.2 | 60 |
| 119 | Lysine acetylation regulates Bruton's tyrosine kinase in B cell activation. *Journal of Immunology*, **2010**, 184, 244-54 | 5.3 | 12 |

| | | | |
|---|---|---|---|
| 118 | HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. *Journal of Molecular Endocrinology*, **2010**, 45, 219-28 | 4.5 | 48 |
| 117 | Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. *Journal of Biological Chemistry*, **2010**, 285, 9429-9436 | 5.4 | 72 |
| 116 | Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. *Journal of Chemical Information and Modeling*, **2010**, 50, 662-76 | 6.1 | 52 |
| 115 | Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. *Pharmacological Research*, **2010**, 62, 3-10 | 10.2 | 33 |
| 114 | TNF/p38α polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. *Cell Stem Cell*, **2010**, 7, 455-69 | 18 | 309 |
| 113 | Chemogenomic profiling of the cellular effects associated with histone H3 acetylation impairment by a quinoline-derived compound. *Genomics*, **2010**, 96, 272-80 | 4.3 | 11 |
| 112 | Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. *Journal of the American Chemical Society*, **2010**, 132, 6827-33 | 16.4 | 223 |
| 111 | Small-molecule chromatin-modifying agents: therapeutic applications. *Epigenomics*, **2010**, 2, 307-24 | 4.4 | 21 |
| 110 | Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 822-39 | 8.3 | 30 |
| 109 | Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. *Journal of Medicinal Chemistry*, **2010**, 53, 1407-11 | 8.3 | 40 |
| 108 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. *Cardiovascular Research*, **2010**, 87, 73-82 | 9.9 | 38 |
| 107 | The specific character of the reaction of derivatives of 2-thioxo-2,3-dihydropyrimidin-4(1H)-one with iodomethane and alkyl chloromethyl sulfides. *Chemistry of Heterocyclic Compounds*, **2010**, 46, 200-205 | 1.4 | 0 |
| 106 | Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI-1). *ChemMedChem*, **2010**, 5, 398-414 | 3.7 | 49 |
| 105 | Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors. *ChemMedChem*, **2010**, 5, 674-7 | 3.7 | 38 |
| 104 | Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors. *ChemMedChem*, **2010**, 5, 1359-72 | 3.7 | 12 |
| 103 | Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. *Proteomics - Clinical Applications*, **2010**, 4, 71-83 | 3.1 | 28 |
| 102 | Nitric oxide determines mesodermic differentiation of mouse embryonic stem cells by activating class IIa histone deacetylases: potential therapeutic implications in a mouse model of hindlimb ischemia. *Stem Cells*, **2010**, 28, 431-42 | 5.8 | 45 |
| 101 | Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. *PLOS Currents*, **2010**, 2, | | 28 |

| | | | |
|---|---|---|---|
| 100 | Histone Deacetylase inhibitors modulate mitochondrial biogenesis in skeletal muscle. *FASEB Journal*, **2010**, 24, lb119 | 0.9 | 1 |
| 99 | Correction for Colussi et al., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 1679-1679 | 11.5 | 78 |
| 98 | Chiral HPLC separation and absolute configuration of novel S-DABO derivatives. *Chirality*, **2009**, 21, 604-12 | 2.1 | 11 |
| 97 | Pyrrole-based hydroxamates and 2-aminoanilides: histone deacetylase inhibition and cellular activities. *ChemMedChem*, **2009**, 4, 1411-5 | 3.7 | 7 |
| 96 | Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors. *Proteomics*, **2009**, 9, 5437-45 | 4.8 | 22 |
| 95 | Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. *EMBO Reports*, **2009**, 10, 776-82 | 6.5 | 109 |
| 94 | Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. *Oncogene*, **2009**, 28, 781-91 | 7.2 | 221 |
| 93 | Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1132-5 | 2.9 | 55 |
| 92 | Reactions of 6-benzyl-5-methyl-2-(methylsulfanyl)pyrimidin-4(3H)-one with aliphatic and aliphatic-aromatic amines. *Russian Journal of Organic Chemistry*, **2009**, 45, 773-776 | 0.7 | 3 |
| 91 | Stereoselective synthesis of 2-substituted 6-[1-(2,6-difluorophenyl)ethyl]-5-methylpyrimidin-4(3H)-ones. *Russian Journal of Organic Chemistry*, **2009**, 45, 1531-1534 | 0.7 | 0 |
| 90 | Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. *International Journal of Biochemistry and Cell Biology*, **2009**, 41, 199-213 | 5.6 | 158 |
| 89 | New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. *International Journal of Biochemistry and Cell Biology*, **2009**, 41, 235-47 | 5.6 | 20 |
| 88 | Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 5496-504 | 8.3 | 117 |
| 87 | "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. *Retrovirology*, **2009**, 6, 52 | 3.6 | 90 |
| 86 | Histone acetyltransferase inhibitors and preclinical studies. *Expert Opinion on Therapeutic Patents*, **2009**, 19, 761-74 | 6.8 | 76 |
| 85 | Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. *Current Pharmaceutical Design*, **2009**, 15, 3940-57 | 3.3 | 63 |
| 84 | Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies. *Current Topics in Medicinal Chemistry*, **2009**, 9, 272-91 | 3 | 37 |
| 83 | Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro.. *Blood*, **2009**, 114, 1978-1978 | 2.2 | |

| | | | |
|---|---|---|---|
| 82 | HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2008**, 1783, 2030-8 | 4.9 | 44 |
| 81 | epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. *Journal of Medicinal Chemistry*, **2008**, 51, 2279-90 | 8.3 | 125 |
| 80 | Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 2341-7 | 5.6 | 12 |
| 79 | HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19183-7 | 11.5 | 212 |
| 78 | Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. *Circulation Research*, **2008**, 102, 51-8 | 15.7 | 106 |
| 77 | Specific activity of class II histone deacetylases in human breast cancer cells. *Molecular Cancer Research*, **2008**, 6, 1908-19 | 6.6 | 82 |
| 76 | Substrate-induced stable enzyme-inhibitor complex formation allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resistant HIV-1 reverse transcriptase mutants. *ChemMedChem* , **2008**, 3, 1412-8 | 3.7 | 7 |
| 75 | Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies. *European Journal of Medicinal Chemistry*, **2008**, 43, 621-32 | 6.8 | 36 |
| 74 | Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2530-5 | 2.9 | 18 |
| 73 | Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2788-92 | 2.9 | 91 |
| 72 | 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. *Journal of Medicinal Chemistry*, **2008**, 51, 4641-52 | 8.3 | 50 |
| 71 | Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains. *Journal of Medicinal Chemistry*, **2007**, 50, 5412-24 | 8.3 | 54 |
| 70 | The therapeutic uses of chromatin-modifying agents. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 835-51 | 6.4 | 47 |
| 69 | Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants. *ChemMedChem*, **2007**, 2, 445-8 | 3.7 | 19 |
| 68 | Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. *ChemMedChem*, **2007**, 2, 987-91 | 3.7 | 48 |
| 67 | Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1221-5 | 2.9 | 75 |
| 66 | Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans. *FEMS Yeast Research*, **2007**, 7, 1371-80 | 3.1 | 31 |
| 65 | Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii. *Antimicrobial Agents and Chemotherapy*, **2007** , 51, 1109-11 | 5.9 | 32 |

| | | | |
|---|---|---|---|
| 64 | Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. *Molecular Pharmacology*, **2007**, 72, 1111-23 | 4.3 | 27 |
| 63 | Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. *Journal of Medicinal Chemistry*, **2007**, 50, 1241-53 | 8.3 | 88 |
| 62 | Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. *International Journal of Biochemistry and Cell Biology*, **2007**, 39, 1510-22 | 5.6 | 11 |
| 61 | Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition. *ChemMedChem*, **2006**, 1, 225-37 | 3.7 | 20 |
| 60 | 6-alkylthio-4-[1-(2,6-difluorophenyl)alkyl]-1H-[1,3,5]triazin-2-ones (ADATs): novel regulators of cell differentiation and proliferation. *ChemMedChem*, **2006**, 1, 1073-80 | 3.7 | 11 |
| 59 | Analytical and semipreparative high performance liquid chromatography separation of stereoisomers of novel 3,4-dihydropyrimidin-4(3H)-one derivatives on the immobilised amylose-based Chiralpak IA chiral stationary phase. *Journal of Separation Science*, **2006**, 29, 1399-406 | 3.4 | 24 |
| 58 | One-Pot, High-Yielding Synthesis of Novel Dihydrothiazolo[3,2-a]pyrimidinones. *Synthetic Communications*, **2006**, 36, 495-500 | 1.7 | 1 |
| 57 | Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. *Cancer Research* , **2006**, 66, 6785-92 | 10.1 | 117 |
| 56 | Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. *Journal of Medicinal Chemistry*, **2006**, 49, 6897-907 | 8.3 | 119 |
| 55 | Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 6046-56 | 8.3 | 51 |
| 54 | 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. *Journal of Chemical Information and Modeling*, **2006**, 46, 1420-30 | 6.1 | 36 |
| 53 | Identification of small molecules inhibitors of GCN5 histone acetyltransferase activity. *Arkivoc*, **2006**, 2006, 24-37 | 0.9 | 5 |
| 52 | Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 7789-95 | 8.3 | 147 |
| 51 | 6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase. *Journal of Medicinal Chemistry*, **2005**, 48, 6776-8 | 8.3 | 43 |
| 50 | Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. *Journal of Medicinal Chemistry*, **2005**, 48, 3344-53 | 8.3 | 179 |
| 49 | 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 2065-77 | 3.4 | 46 |
| 48 | Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 4656-61 | 2.9 | 39 |
| 47 | A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. *Biochemical Pharmacology*, **2005**, 70, 911-7 | 6 | 33 |

| | | | |
|---|---|---|---|
| 46 | Histone deacetylation in epigenetics: an attractive target for anticancer therapy. *Medicinal Research Reviews*, **2005**, 25, 261-309 | 14.4 | 278 |
| 45 | Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. *Medicinal Chemistry*, **2005**, 1, 245-54 | 1.8 | 20 |
| 44 | New 6-nitroquinolones: synthesis and antimicrobial activities. *Il Farmaco*, **2004**, 59, 463-71 | | 16 |
| 43 | Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 1537-41 | 2.9 | 48 |
| 42 | 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. *Journal of Medicinal Chemistry*, **2004**, 47, 1098-109 | 8.3 | 56 |
| 41 | Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylase inhibitors. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1435-6 | 5.9 | 48 |
| 40 | 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. *Journal of Medicinal Chemistry*, **2004**, 47, 1351-9 | 8.3 | 59 |
| 39 | Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. | 8.3 | 80 |
| 38 | Synthesis and biochemical evaluation of (R)-5-acyloxymethyl- and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones as new anti-monoamine oxidase (anti-MAO) agents. *Arkivoc*, **2004**, 2004, 32-43 | 0.9 | 5 |
| 37 | Aroyl-Pyrrolyl-Hydroxy-Amides (APHAs), a Novel Family of Synthetic Histone Deacetylases Inhibitors, Are Potent Inducers of Human g-Globin Gene Expression.. *Blood*, **2004**, 104, 1216-1216 | 2.2 | |
| 36 | Role of endogenous reverse transcriptase in murine early embryo development. *Molecular Reproduction and Development*, **2003**, 66, 225-36 | 2.6 | 59 |
| 35 | Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. *Il Farmaco*, **2003**, 58, 231-41 | | 17 |
| 34 | Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. *Journal of Medicinal Chemistry*, **2003**, 46, 4826-9 | 8.3 | 61 |
| 33 | 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. *Journal of Medicinal Chemistry*, **2003**, 46, 512-24 | 8.3 | 104 |
| 32 | Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. *Journal of Medicinal Chemistry*, **2002**, 45, 1778-84 | 8.3 | 59 |
| 31 | 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. *Journal of Medicinal Chemistry*, **2002**, 45, 1180-3 | 8.3 | 34 |
| 30 | Chiral resolution and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. *Chirality*, **2001**, 13, 75-80 | 2.1 | 24 |
| 29 | Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. *Journal of Medicinal Chemistry*, **2001**, 44, 2544-54 | 8.3 | 76 |

| | | | |
|---|---|---|---|
| 28 | Structure-activity relationship studies on new DABOS: effect of substitutions at pyrimidine C-5 and C-6 positions on anti-HIV-1 activity. *Antiviral Chemistry and Chemotherapy*, **2001**, 12, 37-50 | 3.5 | 22 |
| 27 | A NEW FACILE AND EXPEDITIOUS SYNTHESIS OF N-HYDROXY-N?-PHENYLOCTANEDIAMJDE, A POTENT INDUCER OF TERMINAL CYTODIFFERECNTIATION. *Organic Preparations and Procedures International*, **2001**, 33, 391-394 | 1.1 | 34 |
| 26 | 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. *Journal of Medicinal Chemistry*, **2001**, 44, 2069-72 | 8.3 | 75 |
| 25 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 1651-6 | 2.9 | 19 |
| 24 | 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. *Journal of Medicinal Chemistry*, **1999**, 42, 619-27 | 8.3 | 102 |
| 23 | N-[4-(1,1Rbiphenyl)methyl]-4-(4-thiomorpholinylmethyl) benzenamines as non-oxazolidinone analogues of antimycobacterial U-100480. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 1493-8 | 2.9 | 19 |
| 22 | Arylketotetramethylene Analogues of Disoxaril with Anti-Human Rhinovirus 14 Activity. *Antiviral Chemistry and Chemotherapy*, **1997**, 8, 235-242 | 3.5 | 3 |
| 21 | Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. *Journal of Medicinal Chemistry*, **1997**, 40, 1447-54 | 8.3 | 97 |
| 20 | Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments. *Bioorganic and Medicinal Chemistry*, **1996**, 4, 1715-24 | 3.4 | 12 |
| 19 | Methyl-2-Thienylketopolymethyleneoxyphenyl Derivatives of Alkyl-Substituted 4,5-Dihydro-Oxazoles with Anti-Human Picornavirus Activity. *Antiviral Chemistry and Chemotherapy*, **1996**, 7, 213-220 | 3.5 | 4 |
| 18 | Pyrrolobenzodiazepines with antinociceptive activity: synthesis and pharmacological activities. *European Journal of Medicinal Chemistry*, **1995**, 30, 593-601 | 6.8 | 9 |
| 17 | Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. *Journal of Medicinal Chemistry*, **1995**, 38, 3258-63 | 8.3 | 86 |
| 16 | Synthesis and Antiviral Activity of New 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs), Specific Inhibitors of Human Immunodeficiency Virus Type 1. *Antiviral Chemistry and Chemotherapy*, **1995**, 6, 1-8 | 3.5 | 45 |
| 15 | [[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline derivatives with potent and selective antihuman rhinovirus activity. *Journal of Medicinal Chemistry*, **1995**, 38, 803-9 | 8.3 | 6 |
| 14 | 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1. *Antiviral Chemistry and Chemotherapy*, **1993**, 4, 361-368 | 3.5 | 69 |
| 13 | Antifungal agents, II: Synthesis and antifungal activities of aryl-1H-pyrrol-2-yl-1H-imidazol-1-yl-methane derivatives with unsaturated chains. *Archiv Der Pharmazie*, **1993**, 326, 539-46 | 4.3 | 5 |
| 12 | 5,6-Dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepine-4,4-diacetic acid diethyl ester, an useful synthon for the synthesis of new polycyclic nitrogen systems of pharmacological interest. *Journal of Heterocyclic Chemistry*, **1993**, 30, 897-903 | 1.9 | 7 |
| 11 | Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives. *Journal of Medicinal Chemistry*, **1992**, 35, 4533-41 | 8.3 | 15 |

| | | | |
|---|---|---|---|
| 10 | One-pot synthesis of novel spiro-annelated pyrrole-containing heterocyclic systems from suitable synthons. *Journal of Heterocyclic Chemistry*, **1992**, 29, 241-245 | 1.9 | 11 |
| 9 | Synthesis of pyrazole analogues of isoaptazepine. *Journal of Heterocyclic Chemistry*, **1992**, 29, 1851-1854 | 1.9 | 3 |
| 8 | Pyrrylphenylethanones related to cathinone and lefetamine: synthesis and pharmacological activities. *Archiv Der Pharmazie*, **1992**, 325, 403-9 | 4.3 | 2 |
| 7 | Synthesis of new disoxaril analogues with potent and selective anti-human rhinovirus 14 activity. *Bioorganic and Medicinal Chemistry Letters*, **1991**, 1, 575-578 | 2.9 | 4 |
| 6 | Heterocyclic system. XI. Synthesis of 1H,4H-pyrazolo[4,3-b]pyrrolizine and 2H,4H-pyrazolo[4,3-b]pyrrolizine derivatives. *Journal of Heterocyclic Chemistry*, **1990**, 27, 1805-1808 | 1.9 | 4 |
| 5 | Spiro-[4H-pyrroIo[1,2-a][1,4]benzodiazepine-4,4?-piperidine] Derivatives as Potential Nootropic Agents: A Simple One-Pot Synthesis. *Synthetic Communications*, **1990**, 20, 3537-3545 | 1.7 | 8 |
| 4 | Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. *Journal of Medicinal Chemistry*, **1990**, 33, 2845-9 | 8.3 | 24 |
| 3 | Researches on antibacterial and antifungal agents, X. Synthesis and antifungal activities of 1-(p-methyl-alpha-[4-(1H-pyrrol-1-yl)phenyl]benzyl)azoles and some related products. *Archiv Der Pharmazie*, **1989**, 322, 369-73 | 4.3 | 11 |
| 2 | Syntheses of 3b,4,6,7-Tetrahydro-5h,9h-pyrazino [2,1-c] phyrolo[1,2-a] [1,4] benzodiazepine, a valuable precursor of potential central nervous system agents. *Tetrahedron*, **1989**, 45, 2763-2772 | 2.4 | 16 |
| 1 | Synthesis of a new tetracyclic system related to aptazapine (CGS 7525A) by one-pot double annelation. *Tetrahedron Letters*, **1988**, 29, 6471-6474 | 2 | 13 |